AOD9604 (5mg)
$55.99
AOD9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH 177-191), with an additional tyrosine residue at the N-terminus. In research settings, AOD9604 is examined for its interactions with adipocyte signaling pathways and lipolytic mechanisms — studied independently of the growth-promoting effects associated with full-length GH.
BioRhex supplies AOD9604 as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
- In stock
- COA-verified
- ≥99% purity.
- USA manufactured.
- In stock
- COA-verified
- ≥99% purity.
- USA manufactured.
- COA-verified
- In stock
- ≥99% purity.
- USA manufactured.
What Is AOD9604?
AOD9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH 177-191), with an additional tyrosine residue at the N-terminus. In research settings, AOD9604 is examined for its interactions with adipocyte signaling pathways and lipolytic mechanisms — studied independently of the growth-promoting effects associated with full-length GH.
BioRhex supplies AOD9604 as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
Compound Overview
AOD9604 is a GH-derived fragment studied for its adipocyte signaling and metabolic regulatory properties. In vitro and preclinical research examines how AOD9604 may influence:
• Adipocyte lipolysis signaling and fat cell metabolism pathway modeling
• Beta-3 adrenergic receptor pathway interactions in adipose tissue
• Lipogenesis pathway inhibition in adipocyte research models
• Metabolic energy expenditure pathway research
• Preadipocyte differentiation in experimental models
All findings referenced are from controlled research environments and do not represent clinical outcomes or therapeutic claims.
History of AOD9604
AOD9604 was developed by researchers at Monash University in Australia during investigations into the fat-metabolizing properties of growth hormone. Research identified the C-terminal region of GH as retaining lipolytic signaling activity independently of the insulin-like growth-promoting effects of the full molecule.
The isolated and modified fragment became a research tool for studying adipocyte biology and metabolic signaling pathways in the context of GH fragment pharmacology.
Research with AOD9604 continues in the context of adipose tissue biology and lipolytic signaling pathway modeling in laboratory environments.
Molecular Structure
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (hGH fragment 177-191, N-terminal Tyr addition)
Research Findings
Published and preclinical research on AOD9604 covers several areas of scientific investigation, including:
Lipolytic signaling research: Studies examine how AOD9604 interacts with adipocyte intracellular signaling pathways associated with triglyceride metabolism.
Adipogenesis modeling: Research explores AOD9604’s effects on preadipocyte differentiation and adipose cell biology in experimental systems.
Beta-adrenergic pathway interactions: Laboratory models investigate AOD9604’s interactions with adrenergic receptor signaling in adipose tissue.
Metabolic pathway research: Studies evaluate AOD9604’s effects on lipid metabolism markers in preclinical adipocyte models.
All findings referenced are from controlled, non-clinical research models and do not imply therapeutic or clinical application.
References
FAQ
What type of research is AOD9604 used for?
What type of research is AOD9604 used for?
AOD9604 is used in laboratory research settings. All supplied compounds are intended strictly for in vitro and preclinical research purposes. Use is limited to controlled scientific environments.
Where is BioRhex’s AOD9604 manufactured?
Where is BioRhex’s AOD9604 manufactured?
All BioRhex compounds, including AOD9604, are manufactured in a GMP-compliant facility located in the United States.
What testing does BioRhex conduct on AOD9604?
What testing does BioRhex conduct on AOD9604?
Every batch of AOD9604 undergoes third-party HPLC purity testing, mass spectrometry identity verification, and sterility testing. A Certificate of Analysis is included with every order, documenting batch-specific purity data at a ≥99% threshold.
Is AOD9604 approved for human use?
Is AOD9604 approved for human use?
No. AOD9604 is not FDA-approved and is not intended for human or animal administration. It is supplied exclusively for laboratory research purposes.
Who should handle this compound?
Who should handle this compound?
Only qualified personnel in controlled laboratory settings following appropriate safety and handling protocols.
Research Use Only
All BioRhex compounds are supplied strictly for laboratory research purposes. Not for human or animal consumption, medical use, or therapeutic application. AOD9604 is not FDA-approved for any medical purpose. Nothing on this page should be interpreted as health guidance or applied outside controlled research settings.
RELATED PRODUCTS
AOD9604 (5mg)
BPC-157
BPC-157 + TB-500
CJC (no DAC) + Ipamorelin (10mg)
